Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 899376 | ISIN: US5147661046 | Ticker-Symbol: LDE
Frankfurt
18.04.24
08:02 Uhr
6,000 Euro
-0,050
-0,83 %
1-Jahres-Chart
LIFECORE BIOMEDICAL INC Chart 1 Jahr
5-Tage-Chart
LIFECORE BIOMEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,8006,05018.04.
5,8506,00018.04.

Aktuelle News zur LIFECORE BIOMEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.04.LIFECORE BIOMEDICAL, INC. \DE\ - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB1
01.04.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
26.03.Lifecore Biomedical, Inc.: Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update41CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO")...
► Artikel lesen
21.03.Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal1
20.03.Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session2
20.03.CDMO Lifecore Biomedical names new CEO, board chair after year-long strategic review3
20.03.Lifecore Biomedical: Board Concludes Review; To Execute Strategic Plan As Standalone Company2
20.03.Lifecore Biomedical concludes strategic evaluation process, names new CEO1
20.03.Lifecore Biomedical revises past financial statements3
20.03.Lifecore Biomedical, Inc.: Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes1
20.03.Lifecore Biomedical, Inc.: Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023286CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"or the"Company"), a fully integrated contract development and manufacturing organization ("CDMO")...
► Artikel lesen
20.03.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
16.02.Lifecore faces potential Nasdaq delisting over filing delays2
16.02.Lifecore Biomedical receives Nasdaq notice of delisting1
16.02.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
16.02.Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal329CHASKA, Minn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the "Company") announced today that on February 13, 2024 it received a Staff Delisting Determination (the...
► Artikel lesen
12.01.Lifecore Biomedical receives Nasdaq notice for delayed quarterly reports1
12.01.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
12.01.Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report302CHASKA, Minn., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the "Company") announced today that it received a notice ("Notice") on January 10, 2024 from the Listing...
► Artikel lesen
10.01.LIFECORE BIOMEDICAL, INC. \DE\ - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB1
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1